Abstract 【Objective】To investigate the impact of olanzapine treatment on glycolipid metabolism and blood routine test results in patients with schizophrenia (SCZ).【Methods】A total of 230 SCZ patients were divided into the observation group (118 patients, treated with olanzapine) and the control group (112 patients, treated with risperidone) based on different treatment plans. The efficacy and the changes of glycolipid metabolism and blood routine indicators before and after treatment were compared between the two groups.【Results】The clinical efficacy in the observation group was higher than that in the control group, however, the difference was not statistically significant (P>0.05). After treatment, the scores of the Positive and Negative Syndrome Scale (PANSS) on all dimensions in the observation group were significantly lower than those in the control group (P<0.05). After treatment, the fasting plasma glucose (FPG), total cholesterol (TC), and low-density lipoprotein cholesterol (LDL-C) levels in both groups were significantly lower than before (P<0.05), while triglyceride (TG) level significantly increased (P<0.05). Moreover, the levels of these indicators were significantly lower in the observation group than those in the control group (P<0.05). There were no statistically significant differences in blood routine test results between the two groups before and after treatment (P>0.05).【Conclusion】Olanzapine and risperidone have similar overall therapeutic effects on SCZ patients. However, olanzapine has a more significant advantage in improving glycolipid metabolism and it does not have adverse effects on blood routine indicators.
CHENG Weihong. The Effect of Olanzapine on Glycolipid Metabolism and Blood Routine Results in Schizophrenia Patients[J]. JOURNAL OF CLINICAL RESEARCH, 2025, 42(2): 252-254.
2025, Vol. 42 
